FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 1910 - Disease, Disability, and Injury Prevention and Control Special Emphasis Panel - Authorized by Law

GENERAL INFORMATION

Committee Name	Disease, Disability, and Injury Prevention and Control Special Emphasis Panel	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	1910
Original Establishment Date	10/12/1994	Committee Status	Terminated
Actual Termination Date	4/1/2025	Committee URL	https://www.cdc.gov/faca/committees/ddipcsep/in...
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	Unlimited
Terminated This FY	Yes	Designated Fed Officer Position Title*	Director, FACAP and Committee Management Officer, CDC
Merged This FY		Designated Federal Officer Prefix	Ms.
Current Charter Date	8/17/2024	Designated Federal Officer First Name*	Gladys
Date Of Renewal Charter	8/17/2026	Designated Federal Officer Middle Name	G.
Projected Termination Date		Designated Federal Officer Last Name*	Lewellen
Exempt From Renewal*	No	Designated Federal Officer Suffix	M.B.A., M.P.A.
Specific Termination Authority	E.O. 14217	Designated Federal Officer Phone*	(770) 488-4786
Establishment Authority*	Authorized by Law	Designated Federal Officer Fax*	na
Specific Establishment Authority*	42 USC 217a	Designated Federal Officer Email*	ggl0@cdc.gov
Effective Date Of Authority*	11/17/1962
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Grant Review Committee

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Terminate
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	During Fiscal Year (FY) 2024, the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel reviewed 290 applications for grant, contract solicitation and cooperative agreement assistance to fund a broad range of research and to develop programs. Of the 290 grant, contract and cooperative agreement applications, 114 applications were recommended and approved for funding for a total $75,379,933.
How is membership balanced?*	The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel membership represented expertise pertinent to the respective subject areas of each Special Emphasis Panel and included representation from all areas of the public, and academia. Membership was balanced in terms of geographic, demographic, and points of view represented.
How frequent & relevant are cmte mtgs?*	Meetings are held as necessary to review applications and proposals for research projects, grants, and cooperative agreements. During FY 2024, the Special Emphasis Panels met 36 times. This reflects the continuing critical role of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel in CDC's grant and cooperative agreement review process.
Why advice can't be obtained elsewhere?*	One of the most important methods CDC utilizes to accomplish its mission is through awarding grants. The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel provides comprehensive and reliable evaluations of application reviews and proposals for research projects, grants and cooperative agreements in the areas of the causes, prevention and control of diseases, disabilities, injuries and impairments of public health significance; exposure to hazardous substances in the environment; health promotion and education; and other related activities that promote health and well-being. Reviews are conducted under the highest ethical standards by including federal and private subject matter experts representing diverse populations and interests assuring that the selection of applications meet program requirements with established criteria and best practices. The integrity of the review process, the ability to award and process grants that are credible, equitable, timely and unbiased and CDC's responsiveness to applicants is facilitated by the Panel.
Why close or partially close meetings?	All Special Emphasis Panel meetings were closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The review and discussion of the applications could reveal confidential trade secrets or commercial property such as patentable material and information of a confidential nature, including personal information concerning individuals associated with the applications, the disclosure of which would constitute an unwarranted invasion of personal privacy.
Recommendation Remarks	2025 Secretary Directive-Elimination of Federal Advisory Committees Within the Department of Health and Human Services, Terminated 04.01.2025. EO 14217 Reducing the Scope of the Federal Bureaucracy. The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP) is a grant review committee and does not generate reports. The members of this Special Emphasis Panel (SEP) do not have standing appointments and serve on an as needed basis for meetings throughout the fiscal year. Therefore, the Members list reflects meeting dates, not appointment start and end dates. Members generally serve for 1-day meetings and some members are appointed to the SEP multiple times for multiple meetings. The following members were appointed and served on the SEP multiple times for multiple meetings: Ann Backus (11/14/23, 5/14/2024); Antoine Alston (11/14/23, 2/28/2024, 5/14/2024); Grace Sembajwe (10/5/23, 2/26/2024, 2/28/2024); Guohua Li (2/26/2024, 2/28/2024); Hamid Fonooni (2/26/2024, 2/28/2024); Hang Lee (4/9/2024, 4/10/2024); Helaine Alessio (4/9/2024, 4/10/2024); Homero Harari (11/30/23, 2/26/2024); Huiyun (Henry) Xiang (3/26/2024, 6/13/2024), James Lloyd Michener (5/2/2024, 5/15/2024); Janessa M. Graves (2/26/2024, 4/2/2024); Jeffrey C. Woldstad (10/5/23, 5/13/2024); Jun Wang (2/26/2024, 2/28/2024); Karen L. Heaton (226/2024, 2/28/2024); Kari L. Babski-Reeves (11/30/23, 5/23/2024); Kitty H. Gelberg (5/13/2024, 5/23/2024); Lavanya Vasudevan (4/9/2024, 4/10/2024); Marie-Anne Rosemberg (2/26/2024, 6/13/2024); Maryann Mason (3/12/2024, 3/26/2024); Matthew Asare (5/7/2024, 5/14/2024); Michael L. Pate (11/14/23, 5/14/2024); Mitchel Rosen (2/26/2024, 2/28/2024); Richard John Webby (4/9/2024, 4/10/2024); Ruiwen Zhang (10/5/23, 2/28/2024); Sang D. Choi (2/28/2024, 5/14/2024); Sarah-Jeanne Salvy (4/11/2024, 5/2/2024); Shane Stephen Que Hee (10/5/23, 11/30/23); Tobili Sam-Yellowe (4/9/2024, 4/10/2024); Traci Byrd (2/26/2024, 5/13/2024); Vijay Golla (2/26/2024, 2/28/2024). There were 36 SEP meetings held and 71 Chairs and co-Chairs served on the panel review meetings.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	No
Outcome Trust In Government	Yes	Action Reallocate Resources	No
Outcome Major Policy Changes	No	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	Yes	Action Approved Grants Or Other Payments	Yes
Outcome Improved Service Delivery	No	Action Other	No
Outcome Increased Customer Satisfaction	Yes	Action Comment	N/A
Outcome Implement Laws/Reg Requirements	No	Grants Review*	Yes
Outcome Other	No	Number Of Grants Reviewed	290
Outcome Comment	N/A	Number Of Grants Recommended	114
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$75,379,933.00
Cost Savings Comment	N/A	Grants Review Comment	During fiscal year 2023, the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP) Notice of Funding Opportunity (NOFO) DP24-004 (August 28–31, 2023) was approved for funding of which twenty (20) applications were awarded in the amount of $19,984,250 and $121,110 additional contract costs were paid during FY24. Also, NOFO IP23-006 (March 7, 2023) was approved for funding and one (1) application was awarded $1,000,000 in funding and $3,270 additional contract costs were paid during FY24. In addition, NOFO CE24-001, Panel A (May 16–17, 2023) was approved for funding and five (5) applications were awarded $4,249,508 during FY24 and NOFO CE24-001, Panel B (May 17–18, 2023) was approved for funding and six (6) applications were awarded $5,041,052 for a total dollar value of grants recommended and additional contract costs in FY24 of $105,779,123. In addition, NOFO PAR 18-812 convened on October 5, 2023, and three (3) applications/cooperative agreements were reviewed and $2,500 was requested but unfunded/approved at the time. Also, PS24-039/-042 convened on May 1-2, 2024, and nine (9) applications/cooperative agreements were reviewed and $3,286 was requested but unfunded/approved at the time. Next, OH24-001 convened on May 13-14, 2024, and two (2) applications/cooperative agreements were reviewed and $7,250 was requested but unfunded/approved at the time. Also, NOFO PAR 18-812 #2 convened on June 13, 2024, and two (2) applications/cooperative agreements were reviewed and $1,500 was requested but unfunded/approved at the time. Additionally, OH22-005/-006 #1 convened on November 14, 2023, and four (4) applications/cooperative agreements were reviewed and $2,231,865 was requested and four (4) approved during FY24. Also, OH22-003 convened on November 30, 2023, and nine (9) applications/cooperative agreements were reviewed and $691230 was requested and six (6) approved during FY24. Also, PS24-063 convened on February 22-23, 2024, and nine (9) applications/cooperative agreements were reviewed and $ 1,761,174 was requested and five (5) approved during FY24. Also, OH23-003, Panel A convened on February 26-27, 2024, and five (5) applications/cooperative agreements were reviewed and $3,829,017 was requested and five (5) approved during FY24. Also, OH23-003, Panel B convened on February 28-29, 2024, Panel B, and three (3) applications/cooperative agreements were reviewed and $2,473,689 was requested and three (3) approved during FY24. Also, CE24-034 convened on February 27-28, 2024, and eleven (11) applications/cooperative agreements were reviewed and $ 703844 was requested and two (2) approved during FY24. In addition, CE24-013 convened on March 12-14, 2024, and twenty-five (25) applications/cooperative agreements were reviewed and $2,326,997 was requested and three (3) approved during FY24. Next, CE24-029 convened on March 19, 2024, and seven (7) applications/cooperative agreements were reviewed and $ 201433 and one (1) approved during FY24. Also, SEP CE24-012 convened on March 26, 2024, and six (6) applications/cooperative agreements were reviewed and $1,448,365 was requested and four (4) approved during FY24. In addition, PS24-040 convened on March 28, 2024, and four (4) applications/cooperative agreements were reviewed and $1,002,798 was requested and one (1) approved during FY24. In addition, CE24-030 convened on April 2, 2024, and eight (8) application/cooperative agreements were reviewed and $1,245,323. was requested and three (3) approved during FY24. Also, GH24-033 convened on April 9, 2024, and ten (10) applications/cooperative agreements were reviewed and $610,493 and seven (7) approved during FY24. In addition, GH21-001/-003/GH24-033 convened on April 10, 2024, and twelve (12) applications/cooperative agreements were reviewed and $8,665,754 and five (5) approved during FY24. Next, DP24-031 convened April 10, 2024, and three (3) applications/cooperative agreements were reviewed and $840,802 and one (1) approved during FY24. Also, DP24-081 convened on April 11, 2024, and eleven (11) applications/cooperative agreements were reviewed and $3,216,996 was requested and five (5) approved during FY24. Also, TS24-010 convened on April 9, 2024, and three (3) applications/cooperative agreements were reviewed and $850333 and two (2) approved during FY24. In addition, CE22-003 convened on April 11, 2024, and four (4) applications/cooperative agreements were reviewed and $ 1650043 was requested and four (4) approved during FY24. Also, IP24-046 convened on April 11, 2024, and two (2) applications/cooperative agreements were reviewed and $4,502,846 and one (1) approved during FY24. Also, IP24-045 convened on April 25-26, 2024, and twenty-eight (28) applications/cooperative agreements were reviewed and $14,170,789 was requested and three (3) approved during FY24. Additionally, SIP24-001/-002/-005 convened on April 30, 2024, and twelve (12) applications/cooperative agreements were reviewed and $628,138 was requested and two (2) approved during FY24. In addition, SIP24-003 convened on May 1, 2024, and eleven (11) applications/cooperative agreements were reviewed and $3,097,489 was requested and nine (9) approved during FY24. Next, SIP24-006/-007/-010 convened on May 2, 2024, and seven (7) applications/cooperative agreements were reviewed and $20,711 was requested but unfunded/approved during fiscal year 2024. In addition, SIP24-011/-013 convened on May 7, 2024, and four (4) applications/cooperative agreements were reviewed and $513,066 was requested and one (1) approved during FY24. Also, SIP24-004 convened on May 8, 2024, and three (3) applications/cooperative agreements were reviewed and $361,958 was requested and one (1) approved during FY24. Also, SIP24-008 convened on May 9, 2024, and four (4) applications/cooperative agreements were reviewed and $963,071 was requested and three (3) approved during FY24. Also, OH24-001 convened on May 13-14, 2024, and two (2) applications/cooperative agreements were reviewed and $4,987,418 were requested and one (1) approved during FY24. Next, SIP24-012 convened on May 14, 2024, and five (5) applications/cooperative agreements were reviewed and $1,814,098 was requested and five (5) approved during FY24. In addition, OH22-005/-006 #2 convened on May 14, 2024, and five (5) applications/cooperative agreements were reviewed and $690,480 was requested and one (1) approved during FY24. Next, SIP24-009 convened on May 15, 2024, and seven (7) applications/cooperative agreements were reviewed and $816,383 was requested and three (3) approved during FY24. Next, IP24-017/-081 convened on May 17, 2024, and two (2) applications/cooperative agreements were reviewed and $3,001,911 was requested and one (1) approved during FY24. Also, DP24-138 convened on May 21, 2024, and six (6) applications/cooperative agreements were reviewed and $1,473,369 was requested and three (3) approved during FY24. In addition, OH22-002 convened on May 23, 2024, eight (8) applications/cooperative agreements were reviewed and $548,639 was requested and two (2) approved during FY24. Finally, PAR 20-280/OH24-002/-003/-004 convened on May 28-30, 2024, and thirty-six (36) applications/cooperative agreements were reviewed and $4,145,459 was requested and fifteen (15) approved during FY24.
Number Of Recommendations*	0	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations.	Access Agency Website	Yes
% of Recs Fully Implemented*	0.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	0.00%	Access Publications	No
% of Recs Partially Implemented Comment	The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations.	Access Other	No
Agency Feedback*	Not Applicable	Access Comment	https://www.cdc.gov/faca/committees/ddipcsep/index.html
Agency Feedback Comment*	The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel is a grant application review committee and does not make recommendations. The agency provides the committee and the public information on award funding.	Narrative Description*	The Disease, Disability, and Injury Prevention and Control Special Emphasis Panel shall review applications and proposals for research projects, grants, and cooperative agreements in order to provide advice and guidance to the Secretary, HHS; the Director, Centers for Disease Control and Prevention (CDC), and Administrator, Agency for Toxic Substances and Disease Registry (ATSDR), regarding the concept review, scientific and technical merit of grant and cooperative agreement assistance applications, and contract proposals relating to the causes, prevention, and control of diseases, disabilities, injuries, and impairments of public health significance; exposure to hazardous substances in the environment; health promotion and education; and other related activities that promote health and well-being.

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*	$0.00
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*	$0.00
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*	$0.00
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*	$0.00
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*	$0.00
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*	$0.00
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*	$0.00
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*	$0.00
10. Other Costs		10. Est. Other Costs Next FY*	$0.00
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 9:53 AM	Est. Fed Staff Support Next FY*	0.00
Federal Staff Support (FTE)*		Est Cost Remarks	The SEP was terminated effective March 31, 2025, under E.O. 14217, Commencing the Reduction of the Federal Bureaucracy.
Cost Remarks

Interest Areas

Category Area Agriculture Agriculture Animals Veterinary Medicine Applied Science Engineering Statistics Basic Science Physics Education Education Emergency Disaster Assistance Emergency Preparedness and Management Energy Mining and Minerals Environment Environmental Issues Health Aging Health Care Hospitals Nutrition Physical Fitness Public Health Safety Treatment Labor Occupational Safety and Health Medicine Diseases Health and Health Research Illnesses

Custom Links

Committee Level Reports